Companies › InventisBio
3 active drug programs in 13 registered trials: 5 Phase 2, 5 Phase 1, 3 Phase 3; Oncology, Gastroenterology, Genitourinary, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [14C] D-2570 TYK2 pseudokinase domain inhibitor | TYK2 | Phase 3 | Plaque Psoriasis; UC - Ulcerative Colitis; Psoriasis; PsA (Psoriatic Arthritis) … | Nov 2026 |
| D-0502 | – | Phase 3 | Breast Cancer | Nov 2026 |
| D-1553 KRAS G12C inhibitor | KRAS | Phase 1 | Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07411742 | [14C] D-2570 | Phase 1 | Mass Balance Study | Other | Mar 2026 |
| NCT07270783 | [14C] D-2570 | Phase 1 | Healthy Volunteer | Other | Nov 2026 |
| NCT07715175 | [14C] D-2570 | Phase 1 | Renal Impairment | Genitourinary | Nov 2026 |
| NCT06954961 | D-0502 | Phase 3 | Breast Cancer | Oncology | Nov 2026 |
| NCT07715149 | [14C] D-2570 | Phase 1 | Healthy Adult Participants | Gastroenterology | Nov 2026 |
| NCT07035041 | [14C] D-2570 | Phase 2 | UC - Ulcerative Colitis | Immunology | Dec 2026 |
| NCT07326813 | [14C] D-2570 | Phase 3 | Plaque Psoriasis | Immunology | Jul 2027 |
| NCT07130604 | [14C] D-2570 | Phase 3 | Plaque Psoriasis | Immunology | Jul 2027 |
| NCT07489885 | [14C] D-2570 | Phase 2 | Psoriasis | Immunology | Aug 2027 |
| NCT07315061 | [14C] D-2570 | Phase 2 | PsA (Psoriatic Arthritis) | Immunology | Aug 2027 |
| NCT07625891 | [14C] D-2570 | Phase 2 | Vitiligo | Immunology | Nov 2027 |
| NCT05379946 | D-1553 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
| NCT07311200 | [14C] D-2570 | Phase 2 | Active Systemic Lupus Erythematosus | Immunology | Aug 2028 |
Revolution Medicines Bristol-Myers Squibb Incyte TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly AbbVie Pfizer Amgen
Ranok Therapeutics (Hangzhou) Blueprint Medicines SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Genfleet Therapeutics (Shanghai) Chengdu Zenitar Biomedical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.